News|Articles|August 10, 2026

European Society of Cardiology 2026 Preview: 6 Trials to Know

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

The European Society of Cardiology (ESC) Congress 2026, set to begin on August 28, 2026, in Munich, Germany, will collect some of the biggest trials and most impactful news in cardiology over the last 12 months. From heart failure and stroke to cardiomyopathy and lipid-lowering, every headlining disease state will be addressed during this 3-day conference. Major potential treatments like aficamten and pacibekitug will prove their potential, while data from terminated trials like LIBREXIA ACS and CARDIO-TTRansform will provide valuable insights into future treatment strategies for underrepresented populations.

Related to this article

November 8th, 2026

Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.

November 8th, 2026

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

November 7th, 2026

STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

November 7th, 2026

Asundexian Effect Consistent Across Vascular Risk Levels in OCEANIC-STROKE

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

November 7th, 2026

Understanding the Treatment Gap in Nonobstructive HCM, with Ahmad Masri, MD, MS

Ahmad Masri, MD, MS, discusses the move toward medical therapy in HCM, the nonobstructive treatment gap, and imaging's role in diagnosis and follow-up.